Cytek Biosciences, Inc. (CTKB) stock
CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/309% below fair value
$5.92+0.22 (+3.86%)
Close on Nov 18, 2026Market cap $769.50MP/E –Yield –
Cytek Biosciences profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Cytek Biosciences's profit margin for the twelve months ending Jun 30, 2023 was -3.3%. For fiscal 2025 it was -33.0%, against -3.0% the year before. The highest annual figure on record is 2733.9% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -33.0% | −30.0 |
| FY2024 | Dec 31, 2024 | -3.0% | +3.3 |
| FY2023 | Dec 31, 2023 | -6.3% | −7.8 |
| FY2022 | Dec 31, 2022 | 1.5% | −137.3 |
| FY2021 | Dec 31, 2021 | 138.8% | −2595.2 |
| FY2020 | Dec 31, 2020 | 2733.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -25.3% | −11.5 |
| Q1 FY2026 | Mar 31, 2026 | -42.7% | −33.9 |
| Q2 FY2025 | Jun 30, 2025 | -12.2% | +6.1 |
| Q1 FY2025 | Mar 31, 2025 | -27.5% | −35.2 |
| Q1 FY2024 | Mar 31, 2024 | -13.8% | −17.8 |
| Q2 FY2023 | Jun 30, 2023 | -8.8% | −7.1 |
| Q1 FY2023 | Mar 31, 2023 | -18.4% | −12.2 |
| Q4 FY2022 | Dec 31, 2022 | 7.7% | +10.7 |
| Q3 FY2022 | Sep 30, 2022 | 4.0% | −0.1 |
| Q2 FY2022 | Jun 30, 2022 | -1.7% | −10.5 |
| Q1 FY2022 | Mar 31, 2022 | -6.2% | −6.6 |
| Q4 FY2021 | Dec 31, 2021 | -3.0% | −21.3 |
| Q3 FY2021 | Sep 30, 2021 | 4.1% | −21.9 |
| Q2 FY2021 | Jun 30, 2021 | 8.8% | −33.6 |
| Q1 FY2021 | Mar 31, 2021 | 0.4% | – |
| Q4 FY2020 | Dec 31, 2020 | 18.3% | – |
| Q3 FY2020 | Sep 30, 2020 | 26.1% | – |
| Q2 FY2020 | Jun 30, 2020 | 42.4% | – |
See a number that looks wrong?